Fenproporex is a sympathomimetic agent with a pharmacological profile similar to that of amphetamine. It is available in many countries throughout the world, but it is currently not available in the United States. Because of its stimulant effects, it has a great potential for abuse. To the best of our knowledge, there have been no literature reports of blood or serum concentrations found in therapeutic, toxic, or fatal cases. We report a case where fenproporex was a finding in the death of a young adult. Blood, urine, and gastric contents were analyzed. The following drug concentrations were found: 0.90 mg/L (inferior vena cava blood), 1.2 mg/L (urine), and 120 mg total (gastric) for fenproporex and 0.084 mg/L (inferior vena cava blood), 0.94 mg/t (urine), and 0.14 mg total (gastric) for amphetamine. In addition to the fenproporex, other medications detected and their blood concentrations found in this case were diazepam (0.54 mg/L), nordiazepam (0.46 mg/L), diphenhydramine (0.12 rag/L), and gamma hydroxybutyric acid (GHB) (1100 rag/L).
Introduction
Fenproporex (Fenorex | Tegisec | Antiobes Retard | is a sympathomimetic agent with effects similar to those of dextroamphetamine. It is used as an anorexic adjunct to dietary measures in the short-term treatment of moderate to severe obesity. Chemically it is (+) N-2-cyanoethylamphetamine ((_+)-3-(cz-methylphenethylamino)-propionitrile) (Figure 1 ). It is a weak base with a PKa of 7.23 (1). It is typically given in divided doses of 20 to 25 mg daily, prior to eating. It has also been given in a long-acting preparation in a dose of 20 mg taken prior to breakfast (2) . It is available in 10-and 20-rag dosage forms.
Initially, fenproporex was claimed to be free of amphetamine's stimulatory effects (3, 4) and was recommended as an anorectic drug for treating obese patients with concomitant cardiovascular disease (5) . It is now known to have central stimulatory effects (5, 6) . Abuse of this compound has been described in truck drivers in Brazil (7) . It has also been associated with isolated cases of primary pulmonary hypertension (PPH) (8) , scleroderma (9) , and a subarachnoid hemorrhage (10) .
Fenproporex is rapidly metabolized to at least 14 metabolites (11), the predominant pathway being to amphetamine. The proposed metabolic pathway is given in Figure 1 (11) . It has been shown to undergo an extensive pre-systemic biotransformation, (between 25 and 30% of the dose), either by a first pass effect, by an enzymatic breakdown by the intestinal flora, or some combination thereof (6) . 
Case History
The decedent was a 26-year-old female health care worker in apparently good physical health. She had a past history of at least two overdoses, one involving GHB and the other a diet-pill/sedative combination (the specific medications involved are unknown). The overdoses are believed to be suicidal/attentiongetting in nature.
The autopsy findings showed pulmonary congestion and edema as well as a mitral valve prolapse. There was no other significant pathology. The cause of death was listed as gamma hydroxybutyric acid (GHB) overdose. The manner of death was ruled to be suicide. Blood, urine, gastric contents, and liver were submitted for toxicological analysis.
Materials and Methods

Initial drug screening
The initial screening of the urine sample in this case was by immunoassay (RIA, Diagnostic Products Corporation, Los Angeles, CA and FPIA, Abbott Diagnostics, Chicago, IL) for cannabinoids, benzodiazepines, opiates, barbiturates, benzoylecgonine, and lysergic acid diethylamide (LSD). The urine and gastric contents were screened by thin-layer chromatography (Toxi-Lab | Ansys Technologies, Inc., Lake Forest, CA). Gas chromatography with nitrogen-phosphorus detection (GC-NPD) was also used to screen the blood (12) . All confirmations were performed by gas chromatography-mass spectrometry (GC-MS). Volatile substances in blood were screened by headspace GC. Diphenhydramine and benzodiazepines were quantitated by GC-NPD and confirmed by GC-MS. The fenproporex was detected and confirmed in Pinellas County by GC and GC-MS. The quantitation of fenproporex was performed at National Medical Services.
The analysis of GHB in Pinellas County was a modified method of LeBeau et al. (13, 14) . Gamma-hydroxybutyric acid analysis performed at National Medical Services was by a modification of the method of Ferrara and co-workers (15) .
Analysis of fenproporex
Reagents. Fenproporex was a gift of Rhenochem (Basel, Switzerland). The internal standard, N-propylamphetamine was purchased from Alltech Associates (Deerfield, IL). All of these compounds were used as received. Isopropyl alcohol, petroleum ether (b.p. 30-60~ dichloromethane, and toluene used as solvents were glass-distilled, analytical reagent grade. Sodium hydroxide, hydrochloric acid, butyric anhydride, and 4-dimethylaminopyridine were analytical reagent grade. Folsom, CA). The operating conditions were as follows: helium (carrier gas) at a head pressure of current work 17.5 psi; column oven temperature programmed from 130~ to 300~ at 15~ final time was 1.0 min; both the initial time and inlet purge time were 1.0 min; injector and detector temperatures 28 were 220~ and 300~ respectively. The 3396A integrator was used as the controller for the GC 29 and autosampler but was not used for collecting data or for calculations. The data were collected with a Nelson/PerkinElmer (PE Nelson, San Jose, 30 CA) interface and then processed on an IBM PC.
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Extraction. The extraction procedure for fen- 32 proporex was a modification of that reported by Rivera-Calimlim et al. (16) for chlorpromazine and has been reported previously by Kincaid et al. 100-ram tube containing 1.0 mL of 0.05N hydrochloric acid, vortex mixed for 1 min, and centrifuged for 5 min at 1400 x g. For the final extraction stage, the lower aqueous layer was transferred to a 12 x 75-ram test tube containing 0.1 mL of 5% NaOH and briefly vortex mixed. 3~vo-hundred microliters of dichloromethane was added, followed by vortex mixing for 1 min, centrifuging for 2 min at 1400 x g, followed by transfer of the bottom organic layer to a 6 x 50-mm tube containing 3 lJL of butyric anhydride and 0.3 IJg of 4-dimethylaminopyridine as catalyst. The tubes were then heated at 70~ until just dryness. The derivatized residue was reconstituted with 50 IJL of toluene and transferred to a 12 x 32-mm clear autosampler glass vial that had a 0.25-mL clear shell vial insert (Kimble Glass, Kimble-Kontes, Vineland, N J). The vial was sealed, and 1.0 IJL was injected for GC analysis. This method was found to be linear from 0.001 mg/L to 0.50 mg/L and has an excellent correlation (r = 0.9998). A chromatogram of the blood extract in this case is shown in Figure 2 . The mass spectrum of fenproporex is shown in Figure 3 .
Results and Discussion
The analytical results are given in Table I . The blood concentration of gamma hydroxybutyric acid in this case is well above reported concentrations associated with fatal outcomes (Table  II) , and far above levels associated with postmortem formation (18) (19) (20) . The high concentration of GHB in the urine further confirms the high blood concentration. It is believed that GHB is most likely the main causative agent in the demise of this individual. In addition, there were other central nervous system depressants found in this instance which would have contributed to the death through at least additive effects to those of GHB.
The role that the fenproporex played in this case is difficult to determine. There are no known literature reports of fenproporex concentrations in humans to serve as a guide for interpretation. Fenproporex appears to be less toxic than amphetamine having an oral LDso in mice of 65 mg/kg versus 22 mg/kg for their respective racemic mixtures (Table III) . In humans fatal concentrations of amphetamine are reported to range from 0.5 mg/L to 41 mg/L with an average of 8.6 mg/L (21). Death from an amphetamine overdose is typically not a rapid process, but occurs over a course of several hours (21) . It usually occurs from a cardiovascular event such as ventricular fibrillation or left ventricular failure, a cerebrovascular event such as an intracranial hemorrhage, or as a hyperthermic event resulting in rhabdomyolysis or seizures (22) (23) (24) .
The gastric contents of the decedent contained the equivalent of 6-12 tablets, indicating that the fenproporex was still in the absorptive phase. Also, the fenproporex levels found in this case are at a much higher concentration than the amphetamine in both the blood and urine. Beckett et al. (6) observed that an oral dose of fenproporex undergoes a rapid N-dealkylation to amphetamine and that its conversion is complete within 4 h of an ingestion of a single 10-mg dose. In that paper, they further observed that between 25 and 30% of the oral dose enters the circulation as amphetamine, by a first pass through the liver, metabolism by the gut flora, or some combination thereof. Beckett et al.'s (6) data demonstrated that the half-life of this compound was approximately 2 h (2.35 and 1.78). Cody and coworkers (25, 26) reported that at times greater than 3 h after a 10-mg oral dose the amphetamine concentrations in the urine were greater than the fenproporex concentrations. From these results, it is surmised that this woman's death most likely occurred within 3 h of the fenproporex ingestion. Given the usual length of time required for a fatal event with this type of medication, and the proximity of the time of death to the time of ingestion, these levels of fenproporex most likely do not represent a fatal concentration. The amount of fenproporex remaining in the gastric contents indicate that the total dose consumed was supra-therapeutic, most likely a toxic amount and potentially even fatal. It is believed that the large amount of this medication that remained in the gastric contents indicates that the blood levels are above what would be considered therapeutic and are probably in the toxic range for fenproporex. The blood GI-IB concentration in this case is significantly higher than most of the reported GHB concentrations in cases with fatal outcomes (Table I ). In addition, the presence of the diazepam, nordiazepam and diphenhydramine would potentiate the CNS depressant effects of the GHB. As such, it would be expected that if the fenproporex had contributed to the death of this woman, the GHB concentrations would have been lower. It is therefore concluded that even though the levels of fenproporex in this case are most likely in or near the toxic range, this compound was not an immediate cause of the death of this person.
